On the public citation graph

COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature

0 signed · 80 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2020.6775openalex-snapshot
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
inferredcites →https://doi.org/10.1001/jamainternmed.2020.6252openalex-snapshot
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
inferredcites →https://doi.org/10.1002/jmv.22199openalex-snapshot
Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings
inferredcites →https://doi.org/10.1007/s10238-020-00671-yopenalex-snapshot
Emerging treatment strategies for COVID-19 infection
inferredcites →https://doi.org/10.1007/s10620-018-5042-3openalex-snapshot
Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists
inferredcites →https://doi.org/10.1007/s10620-020-06725-1openalex-snapshot
Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment
inferredcites →https://doi.org/10.1007/s12072-020-10054-wopenalex-snapshot
Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations
inferredcites →https://doi.org/10.1007/s15010-012-0305-yopenalex-snapshot
Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma
inferredcites →https://doi.org/10.1007/s15010-016-0891-1openalex-snapshot
Occult HBV infection in the oncohematological setting
inferredcites →https://doi.org/10.1016/j.cell.2020.02.052openalex-snapshot
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
inferredcites →https://doi.org/10.1016/j.cgh.2020.04.002openalex-snapshot
Clinical Features of COVID-19-Related Liver Functional Abnormality
inferredcites →https://doi.org/10.1016/j.cgh.2020.06.017openalex-snapshot
Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection
inferredcites →https://doi.org/10.1016/j.cmi.2020.12.011openalex-snapshot
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)
inferredcites →https://doi.org/10.1016/j.cmi.2021.11.007openalex-snapshot
ESCMID COVID-19 living guidelines: drug treatment and clinical management
inferredcites →https://doi.org/10.1016/j.dld.2018.09.010openalex-snapshot
The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy
inferredcites →https://doi.org/10.1016/j.idc.2020.02.009openalex-snapshot
Hepatitis B Virus Reactivation Potentiated by Biologics
inferredcites →https://doi.org/10.1016/j.jhep.2017.03.021openalex-snapshot
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
inferredcites →https://doi.org/10.1016/j.jhep.2020.05.002openalex-snapshot
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19
inferredcites →https://doi.org/10.1016/j.jmii.2017.10.002openalex-snapshot
Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review
inferredcites →https://doi.org/10.1016/j.micpath.2017.12.014openalex-snapshot
HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis
inferredcites →https://doi.org/10.1016/j.tim.2016.05.006openalex-snapshot
Control and Eradication Strategies of Hepatitis B Virus
inferredcites →https://doi.org/10.1016/s0140-6736(21)00676-0openalex-snapshot
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
inferredcites →https://doi.org/10.1016/s2468-1253(20)30057-1openalex-snapshot
Liver injury in COVID-19: management and challenges
inferredcites →https://doi.org/10.1038/s41598-020-59406-4openalex-snapshot
Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
inferredcites →https://doi.org/10.1053/j.gastro.2017.02.009openalex-snapshot
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
inferredcites →https://doi.org/10.1056/nejmoa2002032openalex-snapshot
Clinical Characteristics of Coronavirus Disease 2019 in China
inferredcites →https://doi.org/10.1073/pnas.2005615117openalex-snapshot
Effective treatment of severe COVID-19 patients with tocilizumab
inferredcites →https://doi.org/10.1080/14397595.2020.1832731openalex-snapshot
Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center
inferredcites →https://doi.org/10.1111/1756-185x.14034openalex-snapshot
Risk of hepatitis B reactivation in patients receiving anti‐tumor necrosis factor‐α therapy
inferredcites →https://doi.org/10.1111/1756-185x.14217openalex-snapshot
Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib
inferredcites →https://doi.org/10.1111/eci.13338openalex-snapshot
COVID‐19 and non‐alcoholic fatty liver disease: Two intersecting pandemics
inferredcites →https://doi.org/10.1111/jvh.13362openalex-snapshot
Clinical characteristics in patients with SARS‐CoV‐2/HBV co‐infection
inferredcites →https://doi.org/10.1111/jvh.13410openalex-snapshot
Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy
inferredcites →https://doi.org/10.1111/liv.13496openalex-snapshot
Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct‐acting antiviral treatment for HCV
inferredcites →https://doi.org/10.1111/liv.14774openalex-snapshot
Clinical characteristics of COVID‐19 patients with hepatitis B virus infection — a retrospective study
inferredcites →https://doi.org/10.1136/annrheumdis-2021-221650openalex-snapshot
Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
inferredcites →https://doi.org/10.1136/bmj.m2200openalex-snapshot
Hepatitis B virus persistence and reactivation
inferredcites →https://doi.org/10.1136/bmj.m3379openalex-snapshot
A living WHO guideline on drugs for covid-19 (2020-2023)
inferredcites →https://doi.org/10.1136/gut.2010.208413openalex-snapshot
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy
inferredcites →https://doi.org/10.1155/2018/2931402openalex-snapshot
Recent Advances in HBV Reactivation Research
inferredcites →https://doi.org/10.1186/s40425-019-0808-5openalex-snapshot
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
inferredcites →https://doi.org/10.12998/wjcc.v9.i19.5266openalex-snapshot
COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report
inferredcites →https://doi.org/10.17863/cam.70428openalex-snapshot
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
inferredcites →https://doi.org/10.3389/fmed.2021.706482openalex-snapshot
Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era
inferredcites →https://doi.org/10.3389/fonc.2021.662746openalex-snapshot
More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study
inferredcites →https://doi.org/10.3390/pathogens11050567openalex-snapshot
Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19
inferredcites →https://doi.org/10.3390/pathogens11060652openalex-snapshot
Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19—An Observational Retrospective Study
inferredcites →https://doi.org/10.3748/wjg.v21.i36.10274openalex-snapshot
Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations
inferredcites →https://doi.org/10.3748/wjg.v25.i26.3299openalex-snapshot
Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention
inferredcites →https://doi.org/10.3851/imp3292openalex-snapshot
HBV Reactivation during Direct-Acting Antiviral Therapy in Hepatitis B and C Coinfected Patients Undergoing Haemodialysis
inferredcites →https://doi.org/10.4254/wjh.v6.i6.384openalex-snapshot
Clinical impact of occult hepatitis B virus infection in immunosuppressed patients
inferredcites →https://doi.org/10.4415/ann_21_03_08openalex-snapshot
Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice.
inferredcites →https://doi.org/10.7326/0003-4819-156-10-201205150-00013openalex-snapshot
Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable
inferredcites →https://doi.org/10.7759/cureus.8645openalex-snapshot
COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4775921openalex-extracted
Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Treatment with Omicron BA.5 Infection: A Retrospective Study in South China
inferred← citeshttps://doi.org/10.1007/s00520-022-07525-1openalex-snapshot
Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204
inferred← citeshttps://doi.org/10.1007/s10096-023-04599-5openalex-snapshot
Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
inferred← citeshttps://doi.org/10.1007/s12328-024-01984-1openalex-snapshot
Spontaneous reactivation of hepatitis B virus with multiple novel mutations in an elderly patient with resolved hepatitis B virus infection
inferred← citeshttps://doi.org/10.1007/s40278-022-24480-7openalex-snapshot
Dexamethasone/immune-globulin/methylprednisolone
inferred← citeshttps://doi.org/10.1016/j.jcvp.2023.100167openalex-snapshot
SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection
inferred← citeshttps://doi.org/10.1016/j.livres.2024.11.003openalex-snapshot
Patients with chronic hepatitis B under nucleos(t)ide analog therapy with Omicron BA.5 infection: A retrospective study in South China
inferred← citeshttps://doi.org/10.1080/17460794.2025.2483122openalex-snapshot
The reactivation of the various types of viruses following COVID-19 infection: a systematic review
inferred← citeshttps://doi.org/10.1093/ofid/ofaf013openalex-snapshot
Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1155/2023/6908757openalex-snapshot
Analysis of HBV and COVID‐19 Coinfection Model with Intervention Strategies
inferred← citeshttps://doi.org/10.1186/s12879-024-10324-0openalex-snapshot
Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B
inferred← citeshttps://doi.org/10.1186/s12985-025-03034-9openalex-snapshot
Epidemiological characteristics of hepatitis B virus infection in adult patients before, during and after COVID-19 in China
inferred← citeshttps://doi.org/10.12677/acm.2023.1361268openalex-snapshot
Research Progress of COVID-19 Vaccination in Patients with Chronic Liver Diseases
inferred← citeshttps://doi.org/10.12998/wjcc.v10.i36.13167openalex-snapshot
Living with liver disease in the era of COVID-19-the impact of the epidemic and the threat to high-risk populations
inferred← citeshttps://doi.org/10.1371/journal.pone.0323708openalex-snapshot
Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B
inferred← citeshttps://doi.org/10.14309/crj.0000000000001397openalex-snapshot
Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection
inferred← citeshttps://doi.org/10.14744/hf.2023.2023.0025openalex-snapshot
Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications
inferred← citeshttps://doi.org/10.26442/00403660.2024.05.202707openalex-snapshot
Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review
inferred← citeshttps://doi.org/10.3390/jcm13206032openalex-snapshot
Risk of Hepatitis B Virus Reactivation in COVID-19 Patients Receiving Immunosuppressive Treatment: A Prospective Study
inferred← citeshttps://doi.org/10.3390/livers3030026openalex-snapshot
Can Hepatitis B Virus (HBV) Reactivation Result from a Mild COVID-19 Infection?
inferred← citeshttps://doi.org/10.3390/v14122778openalex-snapshot
COVID-19 Vaccination in Patients with Chronic Liver Disease
inferred← citeshttps://doi.org/10.3748/wjg.v28.i42.6017openalex-snapshot
COVID-19 associated liver injury: A general review with special consideration of pregnancy and obstetric outcomes
inferred← citeshttps://doi.org/10.3748/wjg.v28.i46.6599openalex-snapshot
Correlation between COVID-19 and hepatitis B: A systematic review
inferred← citeshttps://doi.org/10.3748/wjg.v29.i3.425openalex-snapshot
COVID-19 and hepatic injury: Diversity and risk assessment
inferred← citeshttps://doi.org/10.5501/wjv.v11.i6.453openalex-snapshot
Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective
inferred← citeshttps://doi.org/10.7326/aimcc.2024.0253openalex-snapshot
Hepatitis B Reactivation Following COVID-19
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.